ALNFL — Nfl Biosciences SAS Balance Sheet
0.000.00%
Last trade - 00:00
- €13.84m
- €10.36m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | FAS | FAS | FAS | FAS |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Equivalents | ||||
Cash and Short Term Investments | 0.225 | 0.31 | 3.2 | 1.21 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 0.123 | 0.156 | 0.22 | 0.742 |
Prepaid Expenses | ||||
Total Current Assets | 0.348 | 0.468 | 3.56 | 2.26 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0 | 0 | 0.002 | 0.002 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Total Assets | 0.467 | 0.577 | 3.69 | 2.4 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 0.055 | 0.09 | 0.186 | 1.42 |
Long Term Debt | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 0.055 | 0.175 | 0.271 | 1.48 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 0.412 | 0.402 | 3.41 | 0.917 |
Total Liabilities & Shareholders' Equity | 0.467 | 0.577 | 3.69 | 2.4 |
Total Common Shares Outstanding |